University Hospital Plymouth NHS Trust
Welcome,         Profile    Billing    Logout  
 6 Trials 
9 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Shaw, Heather S
TebeMRD, NCT05315258: Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

Recruiting
2
850
Europe
Tebentafusp, IMCgp100
University of Oxford, Immunocore Ltd, Natera, Inc.
Melanoma (Skin), Melanoma, Uveal
06/25
06/26
SCOPE, NCT04079166 / 2018-002844-10: SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The Study)

Recruiting
2
130
Europe
SCIB1 or iSCIB1+ DNA vaccine
Scancell Ltd, Scancell Ltd
Malignant Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV
01/26
01/26
IDE196-009, NCT05907954: (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Recruiting
2
82
Europe, Canada, US, RoW
Darovasertib, IDE196, LXS196
IDEAYA Biosciences
Uveal Melanoma
01/26
01/29
NCT04785365: Long-Term Follow-Up Study of Patients Receiving ATL001

Terminated
2
1
Europe
Biological: ATL001
Achilles Therapeutics UK Limited
Melanoma, Advanced Non Small Cell Lung Cancer
10/23
10/23
IMC-F106C-101, NCT04262466 / 2019-004046-16: Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Hourglass Oct 2024 - Dec 2024 : Data for late-line NSCLC
Recruiting
1/2
727
Europe, Canada, US, RoW
Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy, Brenetafusp and monoclonal antibodies and chemotherapy, Brenetafusp and tebentafusp, Brenetafusp and bevacizumab, Brenetafusp and kinase inhibitors
Immunocore Ltd
Select Advanced Solid Tumors
02/26
08/26
NVG111-101, NCT04763083 / 2020-000820-20: First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies

Recruiting
1
90
Europe
NVG-111
NovalGen Ltd.
Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Non-small Cell Lung Cancer (NSCLC), Malignant Melanoma
12/23
12/25
Highley, Martin
SCOPE, NCT04079166 / 2018-002844-10: SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The Study)

Recruiting
2
130
Europe
SCIB1 or iSCIB1+ DNA vaccine
Scancell Ltd, Scancell Ltd
Malignant Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV
01/26
01/26
Mamas, Mamas
NAGOMI COMPLEX, NCT05705973: Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients

Recruiting
N/A
3000
Europe
Ultimaster Nagomi™
Terumo Europe N.V.
Cardiovascular Disease, Coronary Artery Occlusion, Ischemic Heart Disease
09/26
09/27
Young, Kate
SCOPE, NCT04079166 / 2018-002844-10: SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The Study)

Recruiting
2
130
Europe
SCIB1 or iSCIB1+ DNA vaccine
Scancell Ltd, Scancell Ltd
Malignant Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV
01/26
01/26
Aroori, Somaiah
No trials found

Download Options